FDA puts GSK's Jemperli on priority review in locally advanced rectal cancer

The US FDA has accepted for priority review GSK's supplemental Biologics License Application for dostarlimab (Jemperli) to treat previously untreated stage II and III dMMR/MSI-H locally advanced rectal cancer, with a PDUFA date set for February 2027.

This Wire brief sits within Fusion42's coverage of Biotech, and 4 sources have reported it between 24 Aug 2026 and 25 Aug 2026.